Top View
- Questions for Review
- Gefitinib Efficacy Associated with Multiple Expression of HER Family in Non-Small Cell Lung Cancer
- Product Monograph
- IRESSA, INN-Gefitinib
- Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
- Tyrosine Kinase Inhibitors (Tkis) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
- Lysosomal Sequestration of Sunitinib: a Novel Mechanism of Drug Resistance
- Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
- Cellular Targets of Gefitinib
- Comparison of Skin Toxic Effects Associated with Gefitinib, Erlotinib Hydrochloride, Or Afatinib Treatment
- Volume 9, Number 2
- Gefitinib-Related Gene Signature in Bladder Cancer Cells Identified by a Cdna Microarray
- Open Full Page
- EGFR and Gastrointestinal Stromal Tumor: an Immunohistochemical and FISH Study of 82 Cases
- Antiproliferative Effects of Gefitinib Are Associated with Suppression of E2F-1 Expression and Telomerase Activity
- EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Readministration of EGFR Tyrosine Kinase Inhibitor in Non
- Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
- Targeted Cancer Therapies Learning Goals Cancer
- Reimbursement Criteria for Frequently Requested Drugs
- MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-Mutant Lung Cancer
- Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer
- September 2006
- The Different Central Nervous System Efficacy Among Gefitinib, Erlotinib
- An Open-Label, Randomized Phase 3 Efficacy Study of ASP8273 Vs
- A Comparison Between First-, Second- and Third-Generation Epidermal
- Overview of Molecular Testing in Non-Small-Cell Lung Cancer
- Testosterone-Stimulated Growth of the Rat Prostate May Be Driven by Tissue Hypoxia and Hypoxia-Inducible Factor-1A
- HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- Comparative Analysis of Drug Response and Gene Profiling Of
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine
- Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
- Oral Targeted Therapy for Cancer
- Combination of Vandetanib, Radiotherapy, and Irinotecan in the Lovo Human Colorectal Cancer Xenograft Model
- Fingolimod Sensitizes EGFR Wild‑Type Non‑Small Cell Lung Cancer Cells to Lapatinib Or Sorafenib and Induces Cell Cycle Arrest
- Afatinib and Gefitinib: a Direct Comparison
- Tyrosine Kinase Inhibitors Interstitial Pneumonitis: Diagnosis and Management
- Gefitinib RIP2 Tyrosine Kinase Inhibitor Catalog # Tlrl-Gef
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- Brain Distribution of a Panel of EGFR Inhibitors Using Cassette-Dosing in Wild-Type and Abcb1/Abcg2 Deficient Mice
- Identification of Genes Linked to Gefitinib
- Progress in Anti-HER2 Targeted Therapy of Metastatic Lung Cancer
- Proliferation of Ewing Sarcoma Cell Lines Is Suppressed by the Receptor Tyrosine Kinase Inhibitors Gefitinib and Vandetanib Mattias K Andersson* and Pierre Åman
- Gefitinib: Drug Information
- Vandetanib Inhibits Both VEGFR-2 and EGFR Signalling at Clinically Relevant Drug Levels in Preclinical Models of Human Cancer
- Vandetanib Is Effective in EGFR-Mutant Lung Cancer Cells with PTEN Deficiency
- New Target Therapies in Advanced Non-Small Cell Lung Cancer: a Review of the Literature and Future Perspectives
- Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2
- Targeted Lung Cancer Therapy: What Have We Learned from Gefitinib?
- Efficacy and Safety of Afatinib for EGFR-Mutant Non-Small Cell Lung Cancer, Compared with Gefitinib Or Erlotinib
- The Tale of HER2